NEKTAR THERAPEUTICSNKTR
ASignal's systematic analysis rates NKTR as Neutral.
Reflects the latest available analysis · analyzed Sep 29, 2026
The case on NKTR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong liquidity position with current ratio of 10.42x
- Low debt-to-equity ratio of 0.15x indicating conservative capital structure
- High cash reserves with $684.34M in total cash
- RSI at 23.7 suggests potential oversold condition
- Negative free cash flow of $-134.77M
- Negative operating and net margins (operating margin: -412.23%, net margin: -287.84%)
- Declining revenue growth (YoY: -9.30%)
- Negative EV/EBITDA of -11.65x indicating unprofitability
- MACD below signal line with negative histogram suggesting bearish momentum
- Price below both SMA20 and SMA50 indicating downtrend
See the full verdict on NKTR
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NKTR
Most investors never get a second opinion, let alone several. ASignal runs NKTR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.